DOP2010000112A - Productos quimioterapeuticos cristalinos - Google Patents
Productos quimioterapeuticos cristalinosInfo
- Publication number
- DOP2010000112A DOP2010000112A DO2010000112A DO2010000112A DOP2010000112A DO P2010000112 A DOP2010000112 A DO P2010000112A DO 2010000112 A DO2010000112 A DO 2010000112A DO 2010000112 A DO2010000112 A DO 2010000112A DO P2010000112 A DOP2010000112 A DO P2010000112A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- indazol
- Prior art date
Links
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Forma cristalina 1 de N-[4-(3-amino-1 H-indazol-4-il)fenil]-N'-(2-fluoro-5metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y metodos de tratamiento de pacientes que padecen una enfermedad para usarla.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98125307P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2010000112A true DOP2010000112A (es) | 2010-07-15 |
Family
ID=40174807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2010000112A DOP2010000112A (es) | 2007-10-19 | 2010-04-16 | Productos quimioterapeuticos cristalinos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7960564B2 (es) |
| EP (1) | EP2195301A1 (es) |
| JP (1) | JP2011500707A (es) |
| KR (1) | KR20100085987A (es) |
| CN (1) | CN101827824B (es) |
| AU (1) | AU2008312533A1 (es) |
| BR (1) | BRPI0818334A2 (es) |
| CA (1) | CA2699354A1 (es) |
| CO (1) | CO6280484A2 (es) |
| CR (1) | CR11443A (es) |
| DO (1) | DOP2010000112A (es) |
| EC (1) | ECSP10010176A (es) |
| GT (1) | GT201000100A (es) |
| MX (1) | MX2010004290A (es) |
| PA (1) | PA8800601A1 (es) |
| RU (1) | RU2010119919A (es) |
| UA (1) | UA99489C2 (es) |
| WO (1) | WO2009052230A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
| WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| SI1638941T1 (sl) * | 2003-05-22 | 2010-11-30 | Abbott Lab | Inhibitorji indazol benzizoksazol in benzizotiazol kinaze |
| DE102005033100B3 (de) * | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| JP4989476B2 (ja) * | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| US20070104780A1 (en) | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,893 patent/US7960564B2/en not_active Expired - Fee Related
- 2008-10-16 MX MX2010004290A patent/MX2010004290A/es active IP Right Grant
- 2008-10-16 AU AU2008312533A patent/AU2008312533A1/en not_active Abandoned
- 2008-10-16 UA UAA201006027A patent/UA99489C2/ru unknown
- 2008-10-16 CA CA2699354A patent/CA2699354A1/en not_active Abandoned
- 2008-10-16 KR KR1020107010996A patent/KR20100085987A/ko not_active Application Discontinuation
- 2008-10-16 CN CN2008801119453A patent/CN101827824B/zh not_active Expired - Fee Related
- 2008-10-16 BR BRPI0818334A patent/BRPI0818334A2/pt not_active IP Right Cessation
- 2008-10-16 RU RU2010119919/04A patent/RU2010119919A/ru not_active Application Discontinuation
- 2008-10-16 EP EP08840532A patent/EP2195301A1/en not_active Withdrawn
- 2008-10-16 WO PCT/US2008/080067 patent/WO2009052230A1/en active Application Filing
- 2008-10-16 JP JP2010530093A patent/JP2011500707A/ja active Pending
- 2008-10-17 PA PA20088800601A patent/PA8800601A1/es unknown
-
2010
- 2010-04-16 DO DO2010000112A patent/DOP2010000112A/es unknown
- 2010-04-16 GT GT201000100A patent/GT201000100A/es unknown
- 2010-04-27 CO CO10049268A patent/CO6280484A2/es not_active Application Discontinuation
- 2010-05-14 EC EC2010010176A patent/ECSP10010176A/es unknown
- 2010-05-19 CR CR11443A patent/CR11443A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500707A (ja) | 2011-01-06 |
| AU2008312533A1 (en) | 2009-04-23 |
| PA8800601A1 (es) | 2009-05-15 |
| MX2010004290A (es) | 2010-04-30 |
| ECSP10010176A (es) | 2010-06-29 |
| CN101827824B (zh) | 2012-10-03 |
| EP2195301A1 (en) | 2010-06-16 |
| GT201000100A (es) | 2012-04-12 |
| US7960564B2 (en) | 2011-06-14 |
| CN101827824A (zh) | 2010-09-08 |
| BRPI0818334A2 (pt) | 2017-05-16 |
| US20090124815A1 (en) | 2009-05-14 |
| WO2009052230A1 (en) | 2009-04-23 |
| KR20100085987A (ko) | 2010-07-29 |
| CR11443A (es) | 2010-09-27 |
| CO6280484A2 (es) | 2011-05-20 |
| RU2010119919A (ru) | 2011-11-27 |
| UA99489C2 (en) | 2012-08-27 |
| CA2699354A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121017T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
| UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000111A (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000113A (es) | Productos quimioterapeuticos cristalinos | |
| PA8800501A1 (es) | Productos quimioterapeuticos cristalinos | |
| DOP2010000115A (es) | Productos quimioterapeuticos cristalinos derivados de indazol | |
| CR9074A (es) | Agente para la profilaxis o tratamiento del sindrome metabolico | |
| IL171927A0 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| ITRM20030504A1 (it) | Cura del calazio. | |
| CR7755A (es) | Thiazolibifenilamidas |